相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ClinVar: improving access to variant interpretations and supporting evidence
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2018)
Reactivating TP53 signaling by the novel MDM2 inhibitor DS3032b as a therapeutic option for high-risk neuroblastoma
Viktor Arnhold et al.
ONCOTARGET (2018)
p38 but not p53 is responsible for UVA-induced MCPIP1 expression
Lukasz Skalniak et al.
MECHANISMS OF AGEING AND DEVELOPMENT (2018)
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Luis A. Carvajal et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma
Chiao-En Wu et al.
BRITISH JOURNAL OF CANCER (2018)
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Audrey Laroche-Clary et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
Veronica Tisato et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model
Emilie A. Chapeau et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
Maryam Zanjirband et al.
ONCOTARGET (2017)
MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
Audrey Laroche et al.
ONCOTARGET (2017)
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
Alan Van Goethem et al.
ONCOTARGET (2017)
Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G0/G1 Arrest by Inhibiting Deubiquitinase USP2a
Katarzyna Magiera et al.
CELL CHEMICAL BIOLOGY (2017)
Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument
Pascal Furet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388)
Frank Herting et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
Christian Lehmann et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner
Arman Esfandiari et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Initial Testing (Stage 1) of MK-8242A Novel MDM2 Inhibitorby the Pediatric Preclinical Testing Program
Min H. Kang et al.
PEDIATRIC BLOOD & CANCER (2016)
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung et al.
NATURE COMMUNICATIONS (2016)
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
Catherine J. Drummond et al.
ONCOTARGET (2016)
Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo
C. Gianna Hoffman-Luca et al.
CLINICAL CANCER RESEARCH (2015)
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
Philipp Holzer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma
Doris Phelps et al.
PEDIATRIC BLOOD & CANCER (2015)
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
Lindi Chen et al.
ONCOTARGET (2015)
An automated fitting procedure and software for dose-response curves with multiphasic features
Giovanni Y. Di Veroli et al.
SCIENTIFIC REPORTS (2015)
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097
Sebastien Jeay et al.
ELIFE (2015)
SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
Shaomeng Wang et al.
CANCER RESEARCH (2014)
Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
Mariko Yoshimura et al.
CANCER SCIENCE (2014)
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development
Daqing Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Selective and Potent Morpholinone Inhibitors of the MDM2-p53 Protein-Protein Interaction
Ana Z. Gonzalez et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo Kian Hoe et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models
Christian Tovar et al.
CANCER RESEARCH (2013)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
Bernard Leroy et al.
NUCLEIC ACIDS RESEARCH (2013)
In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
Siau Jia Wei et al.
PLOS ONE (2013)
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Mark Wade et al.
NATURE REVIEWS CANCER (2013)
NIH Image to ImageJ: 25 years of image analysis
Caroline A. Schneider et al.
NATURE METHODS (2012)
SIFT web server: predicting effects of amino acid substitutions on proteins
Ngak-Leng Sim et al.
NUCLEIC ACIDS RESEARCH (2012)
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
M. H. Aziz et al.
ONCOGENE (2011)
Two-phase dynamics of p53 in the DNA damage response
Xiao-Peng Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
M. Michaelis et al.
CELL DEATH & DISEASE (2011)
Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma Evidence for p53-transcription-dependent and -independent pathways
Manujendra N. Saha et al.
CANCER BIOLOGY & THERAPY (2010)
p53 at a glance
Colleen A. Brady et al.
JOURNAL OF CELL SCIENCE (2010)
MCF-7 breast carcinoma cells do not express caspase-3
Reiner U. Jaenicke
BREAST CANCER RESEARCH AND TREATMENT (2009)
Pharmacologic p53 Activation Blocks Cell Cycle Progression but Fails to Induce Senescence in Epithelial Cancer Cells
Baoying Huang et al.
MOLECULAR CANCER RESEARCH (2009)
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
Ramiro Paris et al.
CELL CYCLE (2008)
Shaping genetic alterations in human cancer: The p53 mutation paradigm
Thierry Soussi et al.
CANCER CELL (2007)
MDM2 and MDM4: p53 regulators as targets in anticancer therapy
Franck Toledo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
Kensuke Kojima et al.
BLOOD (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Paradigm lost, paradigm found: The re-emergence of hormesis as a fundamental dose response model in the toxicological sciences
EJ Calabrese
ENVIRONMENTAL POLLUTION (2005)
Nucleophosmin regulates the stability and transcriptional activity of p53
E Colombo et al.
NATURE CELL BIOLOGY (2002)
The human genome browser at UCSC
WJ Kent et al.
GENOME RESEARCH (2002)
Initial sequencing and analysis of the human genome
ES Lander et al.
NATURE (2001)
分享论文
